Daily Archives: December 15, 2021

8 Reasons To Play In The 2022 Daily Chess Championship – Chess.com

Posted: December 15, 2021 at 10:34 am

Chess.com is happy to announce the 2022 Daily Chess Championship is starting on December 31, 2021! This traditional daily chess event is open to all Chess.com members and has a prize fund of $5,000 and a special Daily Chess Champion trophy. Don't miss the chance to participate in this massive event by clicking the button below and joining the tournament.

If you're still wondering if this event is right for you, here are eight reasons why you should play:

It's always nice to feel like you're a part of something big. Playing in the 2022 Daily Chess Championship will give you the chance to participate in one of the biggest events of the year! The last edition of this event saw more than 16,000 players enjoying the competitionand that was before The Queen's Gambit helped chess reach new heights.

With chess being at the pinnacle of its popularity and major events like the World Chess Championship and PogChamps propelling the game even further, there's no telling how massive this event will be. Make sure you join it now and become a part of Chess.com's history!

Playing chess is fun, and many will gladly play it for free. But what if someone paid you to do it? By participating in the 2022 Daily Chess Championship, you'll get the chance to claim one of the many prizes we're offering. Join the tournament now to compete for a piece of the $5,000 prize fund! We will award players in many categories, including best video analysis, best social media post, and moreso you don't even need to be among the best chess players to win them!

Daily chess is the perfect way for you to get to know some of the most dedicated and friendly members of Chess.com. It's much easier to strike up a conversation when you're playing a longer game against someone. In daily chess, you'll be playing the same person for a more extended period, so it's easier to start a conversation and make new friends!

Daily chess is not only fun, but it also helps you to improve your chess. Although you can't use engines, you do have permission to reference our opening explorer or opening books. You also get the chance to improve your calculation skills since you can spend a long time on each move calculating multiple lines.

Daily chess allows you to think deeply about every move and calculate all the different available lines. Without feeling time pressure or scrambling to keep your flag from falling, you have the chance to play your most precise game yet. Join the tournament and give yourself a chance to play your own immortal game!

If your New Year's resolutions include having more fun and doing exciting things, the 2022 Daily Chess Championship is a great opportunity for you to start the year on the right track. As you celebrate the beginning of 2022, you can also enjoy the thrill of playing in a worldwide competition that will keep you entertained for a long time!

Many titled players and notable Chess.com staff members play in the Daily Chess Championship. Join the tournament for a chance to play against players such as IM Danny Rensch, NM Sam Copeland, and others!

At the end of the tournament, three lucky (or rather, skilled) players will receive the exclusive Daily Chess Championship trophy. The top three players of the event will be able to display the coveted award on their profiles forever!

Excerpt from:

8 Reasons To Play In The 2022 Daily Chess Championship - Chess.com

Posted in Chess Engines | Comments Off on 8 Reasons To Play In The 2022 Daily Chess Championship – Chess.com

Letter to the editor | People fought for freedom of speech – TribDem.com

Posted: at 10:34 am

According to Dr. Judith Thomas

(Dec. 8, Biden suffers just like everyone else), she doesnt like the First Amendment.

Her words: I am sick and tired of people using the First Amendment, says a lot about their character. I have no doubt she is a doctor, but shes going against the very thing that people have fought and died for.

Without freedom of speech, she wouldnt be commenting in The Tribune-Democrat or have a social existence online. Perhaps the good doctor should be cautious of what she might think before it nips her in the bud?

Wilbert Clark III

Johnstown

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Go here to see the original:
Letter to the editor | People fought for freedom of speech - TribDem.com

Posted in Freedom of Speech | Comments Off on Letter to the editor | People fought for freedom of speech – TribDem.com

Behind the UK governments false flag free speech campaign – Al Jazeera English

Posted: at 10:34 am

Picture two recent scenes at British universities. In one, university staff stand huddled in the cold on picket lines, striking for the second year in a row to protest the sustained deterioration of their working conditions. In the second, students walk out of a college Christmas dinner where they are being subjected to a bigoted tirade by a sleazy tabloid columnist. Their principal and his wife label them pathetic, inadequate and arses.

Who in this scenario can count on the British governments support? Hint: it is not the students who had paid to attend a festive meal, not listen to misogynist and anti-transgender ranting. Nor is it the university staff who may face up to a 40 percent cut in their already modest pensions and an increasingly large number of whom earn low wages on precarious and even zero-hour contracts.

Instead of addressing a very real crisis in teaching and learning conditions that threatens to seriously degrade British universities, Boris Johnsons ministers have thrown their energies into manufacturing a campus free speech crisis. Having deliberately excluded higher education from COVID-19 support, they have spent the pandemic making nonsensical claims about campus cancel culture and crafting legislation to protect exactly the kind of hateful speech Durham University students exercised their right not to listen to. The point is less to enshrine freedom of thought than it is to force discredited ideas upon young people.

The Higher Education Freedom of Speech Bill now progressing through Parliament seeks to prevent invitations to speakers from being rescinded if they are discovered to have peddled discredited or hateful ideas. The legislation targets the tactic of no-platforming which was adopted by the National Union of Students in 1974 to stop fascist organisations, like the National Front, from using universities to disseminate their views.

Despite media and political hype, very few have actually been denied platforms in recent years. A 2018 Parliamentary Joint Committee on Human Rights investigation found that there was no wholesale censorship at universities. In a crucial piece of analysis, the independent think tank, Higher Education Policy Institute (HEPI) notes that a 2021 Government White Paper on free speech and academic freedom in higher education preceding the bill ignored the lack of evidence, insisting there was a problem on the basis of a small number of anecdotes, press reports and unspecified concerns.

Is this fake crisis just a classic dead cat distraction to draw attention away from a more substantial attack on a severely underfunded higher education sector also reeling from the damage of Brexit? It is obviously easier to decimate the higher education sector after painting it as intolerant and partisan.

While Universities Minister Michelle Donelan harumphed in outrage about a gender critical professor leaving the University of Sussex of her own will, pursuant to student protests, scores of staff have been made redundant at Goldsmiths University, eliminating entire humanities subjects. That is real cancellation on a scale which deserves our attention.

While gravely concerning, this is only part of the story, for what is at stake for the political right here is the opposite of freedom of expression. As draconian laws effectively criminalise political protest, the goal of the fake crisis is to foist retrograde and discredited ideologies like race science and climate denial upon universities which are among the few remaining spheres where knowledge is valued. An appreciation for truth, critical thinking and facts is therefore deemed indoctrination of students by the left.

Of a piece with the rise of fake news as a vehicle for the rise of right-wing populism, moral panics around free speech aim to legitimise academically unsound or hateful beliefs by giving them the veneer of brave and challenging ideas. Since universities also have a statutory obligation, alongside academic freedom, to uphold academic standards, repudiating specious thought is a scholarly duty, not cancel culture.

Tellingly, the same people who loudly denounce putative silencing on campus have a very good line in cancelling threatening ideas themselves. In late 2020, the Department for Education (DfE) issued guidance deeming anti-capitalism an extremist stance that should not be included in teaching materials for English schools.

In October 2020, Equalities Minister Kemi Badenoch declared that the Government stand unequivocally against critical race theory in education. Since critical race theory is simply a disciplinary framework for talking about race, this restricts discussions of race in schools and colleges.

Last year, then Education Secretary Gavin Williamson warned English universities to adopt the International Holocaust Remembrance Alliances definition of anti-Semitism in its entirety or face sanctions despite widespread concerns. My own university has adopted the IHRA document wholesale even as scores of its academics have warned that some of the examples it gives conflate criticism of the policies, constitutional doctrines and laws of the State of Israel with anti-Semitism, and will silence those who work or speak on the topic of Israel and Palestine.

While universities are hectored like this and told they will be fined if the proposed Free Speech Champion finds them not to have defended free expression robustly, no such strictures seem to apply to the government itself. Shortly after the Home Office abruptly cancelled a speaking engagement with me on colonialism and anti-colonialism for Black History Month this year, a leaked memo warned civil servants to vet speakers opinions and to not invite anyone speakers who had spoken against key government policies. My disinvitation was claimed as a victory by right-wing website, Guido Fawkes.

The sharpest end of governmental cancellation is reserved for those who assess Britains imperial past critically. Attempts to undo silences and amnesia around empire and slavery, or question mindless glorification are frequently met with enraged denunciations of town hall militants, woke worthies and baying mobs, to use Communities Minister Robert Jenricks epithets.

Heritage organisation National Trust has also come under attack. Its Colonial Countryside project which sought to modestly illuminate some colonial and slavery connections for properties in its care was met with political fury from Conservatives. A particular red rag was Winston Churchills family home, Chartwell, in relation to which his imperial connections, hardly a state secret, were mentioned.

After tabloid attacks, academics who had done research on the project were met with verbal abuse and threats. Culture Secretary Oliver Dowden condemned turning the wartime leader into a subject of criticism and controversy. Dowdens warnings to heritage bodies to act in line with government policy or face funding cuts have rightly worried museum staff about political interference in the sector.

Right-wing cancel culture in Britain is at its most implacably repressive when it comes to any mention of Winston Churchill that does not unconditionally glorify him. I have personal experience of this as well, having helped set up a series of talks to examine Churchills links to empire and race at Churchill College Cambridge, the national memorial to him, where I am a fellow.

After only the second event, pursuant to a ferocious and baseless denunciation of the discussion by Policy Exchange, a think tank co-founded by government minister, Michael Gove, the planned series was halted by the college. Policy Exchange rightly described by the HEPI as a partisan think tank with a clear political agenda that mirrors that of the Government was openly jubilant.

The case of Policy Exchange raises questions about the extent to which the concocted free speech crisis is influenced by far-right forces in the United States and their culture war agenda. An expos by Open Democracy last year found that the freedom of speech White Paper, not only cited Policy Exchange (complete with false claims) liberally but also the US-based Alliance for Democratic Freedom International (ADF), a Christian anti-equality organisation which has been classified as a hate group. This organisation has spent 410,000 ($542,000) on lobbying in the UK since 2017, also getting involved in campus disputes.

The Byline Times has just published a report which also raises very serious questions about the shadowy presence on British university campuses of powerful conservative American billionaires who may be funding an anti-equality agenda which includes rehabilitating racist doctrines and gender hierarchies. With a history of supporting extreme right causes in the US, these entities also appear to have influence on UK government higher education policy which now shows a pronounced anti-diversity bent.

British universities are currently nurturing a generation not inclined to toe the conservative line and therefore pillories as woke snowflakes. For that they are being targeted, in a Tory reprise of former US President Richard Nixons dictum, Professors are the enemy, is no surprise. Behind the fabricated cultural battles and false flag free speech campaigns, a real battle is now unfolding, a fight to defend critical thought, robust scholarship, and the right to challenge the line that wealth and power would have us all acquiesce to.

The views expressed in this article are the authors own and do not necessarily reflect Al Jazeeras editorial stance.

Read the original:
Behind the UK governments false flag free speech campaign - Al Jazeera English

Posted in Freedom of Speech | Comments Off on Behind the UK governments false flag free speech campaign – Al Jazeera English

Ink Blog: The First Amendment and the internet – Ashland Daily Press

Posted: at 10:34 am

This week in my POLS 117 (freedom of speech) class at UW-Eau Claire, we end the semester by discussing the freedom of expression on the internet. To understand constitutional protections for expression online, it is useful to recount how the U.S. Supreme Court has interpreted the First Amendment to apply to media that emerged earlier in American history.

The Court has not always found the same level of protection for expression in newer media as it has for the printed word and speech uttered in person. For instance, in Mutual Film Corporation v. Industrial Commission of Ohio (1915), the Court found that movies received no First Amendment protection. The Court overturned this in Burstyn v. Wilson (1952), when the justices held that expression by means of motion pictures is included within the free speech and free press guaranty of the First and Fourteenth Amendments.

The Supreme Court maintains that the First Amendment permits the Federal Communications Commission (FCC) to restrict more expression in broadcast media (radio and television) than the government may regulate in print media. In cases like Red Lion Broadcasting v. FCC (1969) and FCC v. Pacifica Foundation (1978), the Court ruled that the government possesses greater power over broadcast media due to three factors: (1) the long history of its regulation, (2) the scarcity of available frequencies, and (3) its invasive nature.

What about the internet? The foundational case is Reno v. ACLU (1997), where the Court ruled that the government does not possess greater regulatory power online like it does for broadcast media. Regarding the three factors above, the Court in Reno found that those factors are not present in cyberspace.

Put another way, in 1997 there was no long history of government regulation of the internet, there was no structural limit to how many people could produce online content, and the internet was not deemed to be invasive. Therefore, the governments power to regulate the internet is more restricted by the First Amendment. In Reno, the Court spoke positively of the internet as a vast platform from which to address and hear from a world-wide audience of millions of readers, viewers, researchers, and buyers.

As for social media, the Court in Packingham v. North Carolina (2017) reasoned that a fundamental principle of the First Amendment is that all persons have access to places where they can speak and listen, and then, after reflection, speak and listen once more. The Court went on to state the following: While in the past there may have been difficulty in identifying the most important places (in a spatial sense) for the exchange of views, today the answer is clear. It is cyberspace the vast democratic forums of the Internet in general, and social media in particular. Thus, the Court scrutinizes government attempts to ban people from social media.

What about persons who have their accounts removed or suspended by social media companies? While the Constitution protects ones free expression rights from being violated by the government, American courts have not found that the First Amendment restricts what social media companies may do regarding user accounts.

The basis of this approach can be found in a case involving a privately-run cable company, Manhattan Community Access Corporation v. Halleck (2019), where the Supreme Court stated that the Free Speech Clause of the First Amendment constrains governmental actors and protects private actors. Other federal courts have used this reasoning in recent cases to protect social media companies which as private actors possess their own First Amendment rights from laws that would restrict those companies abilities to moderate content or ban/suspend users.

The Supreme Court could eventually overrule or modify some of these precedents, just as it did when overturning Mutual Film Corporation in Burstyn to reinterpret First Amendment protections for movies. Although there are legitimate questions about what powers the government has under the Constitution to regulate social media companies, those companies have not been found to be state actors. Individuals who disapprove of social media companies policies can use their own First Amendment rights to advocate that those companies change their policies. The scope of what the First Amendment protects online is shaped by the Reno, Packingham, and Manhattan Access cases.

Eric T. Kasper is a professor of political science and the director of the Menard Center for Constitutional Studies at UW-Eau Claire. He also serves as the municipal judge for the City of Rice Lake and is a member of the Wisconsin Bar Association.

Read more:
Ink Blog: The First Amendment and the internet - Ashland Daily Press

Posted in Freedom of Speech | Comments Off on Ink Blog: The First Amendment and the internet – Ashland Daily Press

Nicola Sturgeon named as Britain’s greatest foe to freedom of speech – Daily Express

Posted: at 10:34 am

Opponents are concerned that the Hate Crime Bill which passed in March creates a new offence of stirring up hatred which it is feared could stifle or chill public debate.

Offences are considered aggravated if they involve prejudice against a host of characteristics.

Fraser Hudghton, director of case management at the FSU, commented: I [nominated] Nicola Sturgeon for the Hate Crime Act, which has yet to be put into practice because its so unworkable... If it is ever activated it will mean theres less free speech permitted in Scotland that anywhere else in Europe.

Toby Young, the general secretary of the FSU added: The Hate Crime Act is the biggest assault on free speech in the British Isles since the invasion of Julius Caesar in 55 BC. The really scary thing is that the Law Commission wants parliament to pass a similar law in England and Wales.

The Law Commission makes the case for change in England and Wales, stating on its website that aggravated offences only apply in respect of racial and religious hostility whilst the stirring up offences dont cover disability or transgender identity. It also wants new protections for freedom of expression to ensure that only the most egregious hate speech is criminalised and private conversations will be exempted.

The Scottish Government defended its law, with a spokesman saying: The Act does not prevent people expressing controversial, challenging or offensive views nor does it seek to stifle criticism or rigorous debate in any way.

The debate comes as senior Conservative MP John Penrose has made a plea for the UK to avoid adopting culture wars and tribal identity politics which are blamed for pitting different groups against one another in the United States.

He said: Importing US-style culture wars is causing serious damage to hope of a genuinely fair and open British society. [I] argue we must avoid labelling everyone with an indelible, original sin or victimhood based on their race, which god they worship, their gender or anything else.

In his new paper, Poverty Trapped, he makes the case for new measures to ensure fairness in how people are hired and promoted to ensure discrimination and bias do not hold people back.

Mr Penrose wants post-Brexit, post-covid and post-poverty Britain to become a fairer, happier society that wastes less of our human talent, and where the old political battles of class, inequality and jealousy have become quaint historical curiosities.

A major research project last week highlighted enduring intolerance and prejudice. The Woolf Institutes study of anti-semitism on Twitter estimates there are nearly 495,000 explicitly anti-semitic tweets per year made in English that can be seen UK users; it understands there are between 100 and 1,350 explicitly anti-semitic tweets every day in the UK.

See the rest here:
Nicola Sturgeon named as Britain's greatest foe to freedom of speech - Daily Express

Posted in Freedom of Speech | Comments Off on Nicola Sturgeon named as Britain’s greatest foe to freedom of speech – Daily Express

Opinion: To address Yenor, direct your efforts toward the legislature – Boise State University The Arbiter Online

Posted: at 10:33 am

This article was written by Cheyon Sheen, a civil engineering student at Boise State.

With the current uproar of Scott Yenor, I want to mention that 1) signing a petition to further investigate and 2) emailing Marlene Tromp (or anyone else at Boise State) about how he should be fired will not create sustainable change.

Let me give some background information.

There were a ridiculous amount of bills last legislative session that attempted to restrict womens rights, to make it increasingly more difficult to vote, to control and punish Boise State, and to defund diversity, inclusion and equity initiatives. Some of these succeeded. Why do you think the Student Multicultural Center got renamed to just Student Equity?

Last year, H0364 passed in the House of Representatives (thankfully not in the Senate but who knows what will happen next year).

Its statement of purpose was as follows:

This proposed legislation will direct our institutions of higher learning in their responsibility to uphold its student, faculty and staffs Constitutional and First Amendment right to freedom of speech, freedom of expression, freedom to peacefully assemble and more.

Supreme Court language is used to clearly define terms so that free speech in and outside the classroom is understood and protected. Since a significant amount of taxpayer dollars is appropriated to public institutions of higher education each year, and as such, the legislature must ensure that all public institutions of higher education receiving state funds recognize freedom of speech as a fundamental right for all.

Basically, we will defund you, Boise State, if you do anything that violates ones first amendment rights. PASSED 56-12-2. Interesting, because Republicans also claim to want less government control.

I hope students will try to understand why Boise State is only releasing statements about supporting the First Amendment rights and not specifically and publicly addressing Scott Yenor.

Boise State is walking a tightrope with the state legislature. And its not always so black and white.

Even if Boise State could fire this professor (and they cant, because Scott Yenor is tenured), we would be under more scrutiny from the legislature who would further decrease our budget.

There goes your research money, your sports, your departments funding to grow and offer more classes for you to further pursue your education. Though it may seem that Boise State officials are not addressing this and therefore do not support women, they do. They are trying to secure our funding for our education.

If you want to help make Boise State a better place, then please guide your energy into addressing the root problem, the Idaho Legislature.

We have elected officials that support and share the same values as Scott Yenor and these same elected officials vote to defund and lower Boise States budget for all kinds of wack reasons. Last year one of the reasons we lost funding was for indoctrinating students about social justice.

If you dont want people like that to continue to stay in positions of power, then start educating yourself about what is happening at Idahos capitol and start contacting your representatives and let them know how you, as their constituent, want them to vote on bills that concern higher education and womens rights.

If you are from Idaho, find out who your legislators are (maybe they are one of the 52 that voted to pass HB364) and contact them about supporting higher education and womens rights. Especially if you are outside of Ada County.

If you are not from Idaho, register to vote in this state, get involved in this communitys elections. As you reside here, these legislators create laws that directly affect you and your community. Help Idahoans create a better community.

For everyone, when you see organizers asking you to send a letter to your representative, please please please take the time to do so. I hope now you can see more of how these things affect us, especially marginalized communities.

Support organizations that fight to increase education funding, fight for womens rights, voting rights and whatever else you want to see change for the better. You can do this by donating your time, energy and uplifting their voices and sharing whats happening with a friend or two.

Sustainable change starts when you start taking action to address root causes.

With all this said, I want to express extra appreciation, especially as a woman in engineering, for all the staff and faculty at Boise State and within the community who immediately spoke up and are trying to make a change.

Dont let this energy die. We have a long way to go before we make sustainable change.

More here:
Opinion: To address Yenor, direct your efforts toward the legislature - Boise State University The Arbiter Online

Posted in Freedom of Speech | Comments Off on Opinion: To address Yenor, direct your efforts toward the legislature – Boise State University The Arbiter Online

Cybin Awarded Notice of Allowance from US Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety…

Posted: at 10:32 am

- Expands intellectual property portfolio and strengthens position as leading innovator in developing putative psychedelic compounds -

TORONTO--(BUSINESS WIRE)-- Cybin Inc. ( NEO:CYBN) ( NYSE American:CYBN) ( Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics TM today announced that it has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17/394,038 related to CYB004, the Companys investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders. The allowed claims include other forms of deuterated psychedelic tryptamine, notably certain deuterated forms of DMT and 5-MeO-DMT. The patent, which is expected to expire in 2041 before consideration of any patent term extensions, covers composition of matter for the CYB004 drug substance as a putative new chemical entity.

The receipt of this Notice of Allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the Companys dedication to the discovery and development of differentiated psychedelic-based compounds for addressing mental health, said Doug Drysdale, Chief Executive Officer of Cybin. Once issued, this patent may have the opportunity to cover a broad range of claims supporting our IP in psychedelic medicine and further strengthen our emerging best-in-class position in this evolving industry.

According to the U.S. National Institute of Mental Health, anxiety disorders are one of the most common mental illnesses in the U.S., affecting 40 million adults, or approximately 18% of the population every year1. Despite the availability of many prescription medicines, these treatments are not equally efficacious in all patients with up to 50% of patients with general anxiety disorder failing to respond to first line treatments2. Current standardized treatments for anxiety disorders also require chronic administration of medicines that have a long time to onset and present several potential side effects including weight gain, gastrointestinal disturbances, sexual dysfunction and withdrawal symptoms.

CYB004 is a proprietary deuterated psychedelic tryptamine that has the potential to effectively treat anxiety disorders without the well-known side effects of the current treatment landscape, concluded Drysdale.

Cybin continues to pursue multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses.

About Cybin Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings described herein are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin.

Cautionary Notes and Forward-Looking Statements Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybins future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words believe, expect, aim, intend, plan, continue, will, may, would, anticipate, estimate, forecast, predict, project, seek, should or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Companys proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Companys operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the period ended September 30, 2021 and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on http://www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

1)

Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-335. doi:10.31887/DCNS.2015.17.3/bbandelow

2)

Ansara ED. Management of treatment-resistant generalized anxiety disorder. Ment Health Clin. 2020;10(6):326-334. Published 2020 Nov 5. doi:10.9740/mhc.2020.11.326

View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005174/en/

See the original post:

Cybin Awarded Notice of Allowance from US Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety...

Posted in Psychedelics | Comments Off on Cybin Awarded Notice of Allowance from US Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety…

TGA blocks bid to have MDMA, magic mushrooms used to treat mental health conditions – ABC News

Posted: at 10:32 am

Australia's medicines regulator has rejected a call to legalise psychedelic drugs for use in mental health settings.

The Theraputic Goods Administration (TGA) has rejected an application to amend current poisons regulations to allow for psilocybin also known as magic mushrooms and MDMA (methylenedioxymethamphetamine) to be used in medically controlled environments.

Following research findings here and abroad, the application soughtto have the drugs used as part of psychotherapy treatment for mental illnesses,depression and post-traumatic stress disorder.

TGA's decision means the drugs will not be downscaled from Schedule 9 drugs, which are prohibited substances, to Schedule 8 drugs which are controlled substances.

The TGA's stance is the same as its earlier interim decision.

"I am satisfied that psilocybin poses a high danger for both acute and long-term effects if abused or misused by way of access outside of strictly controlled medical and scientific research settings," the author of the final decision, who is not named, said.

"Given this increased risk to individuals of acute and long-term effects, a high level of control across the supply chain commensurate with Schedule 9 is warranted."

Earlier this year, an expert panel review commissioned by the TGA found that psychedelics could possibly be used to manage treatment-resistant mental illnesses in closely supervised medical settings.

"I agree with the committee that the preliminary findings from clinical trials although still in early phases evaluated by the panel are promising," the decision's author said.

"However, given the extent and issues with the quality of the completed studies detailed by the panel, I reiterate my statement in my interim decision that I consider that evidence is still emerging, and the therapeutic value of psilocybin has not been established.

A trial to help terminally ill patients confront their "terror" through the use of a psychedelic compound is the kind of treatment advocates had hoped would become more widely available, before yesterday's rejection from the drug regulator.

"I am of the view that ensuring administration of psilocybin according to the strict protocols used in clinical trials that have showed promise of efficacy to date would be hard to achieve outside a clinical trial framework."

On the use of MDMA in clinical settings, the TGA's decision outlined similar concerns to those it had about psilocybin.

"I consider that the benefits of MDMA have not been fully established, although there is emerging evidence in treating PTSD, with [a] demonstrated low risk of adverse events in controlled settings," the decision said.

"I am concerned with how, in accordance with the qualification included in the expert report's conclusion about the promise of MDMA in highly selected populations, namely the controlled clinical trial environment, can be replicated in real-world settings.

"I have considered the impacts on public health, were access to MDMA to be increased through an entry in Schedule 8 of the Poisons Standard I am of the view that there would be an increased risk of misuse by individuals outside of a highly controlled environment or diversion for illicit purposes."

Read this article:

TGA blocks bid to have MDMA, magic mushrooms used to treat mental health conditions - ABC News

Posted in Psychedelics | Comments Off on TGA blocks bid to have MDMA, magic mushrooms used to treat mental health conditions – ABC News

PharmaTher Announces Positive Research Results for LSD Microneedle Patch – Yahoo Finance

Posted: at 10:32 am

Delivering LSD via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness

Pursuing Phase 2 clinical studies in 2022 with LSD and notable psychedelics

TORONTO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has successfully completed its first research study evaluating MicroDose-MN, a proprietary microneedle (MN) patch for the intradermal delivery of psychedelics, in delivering lysergic acid diethylamide (LSD). These results provide support to file for an IND application with the FDA to conduct Phase 2 clinical studies in 2022 with LSD for various indications.

The aim of PharmaThers research program was to develop a suitable prototype of MicroDose-MN patch for transdermal (intradermal) drug delivery to confirm compatibility and suitability to deliver LSD. The research program scope included, full characterization of LSD conjugated on the microneedle patch backbone, establishment and demonstration of the loading capacity for LSD, and release rate evaluations for the LSD conjugated materials using appropriate models that will be used to support the Companys IND application with the FDA in the future.

The Companys research program with LSD conjugated microneedles have been successfully fabricated, optimized, and characterized. Both structural aspects and ex-vivo skin insertion assessments of the LSD conjugated microneedles have demonstrated successful fabrication and acceptable performance. The incorporation of LSD into microneedles without issue and the ability to demonstrate complete ex vivo skin model release over several days demonstrates potential for larger doses and modified release profiles. With these results, the Company believes it has an acceptable prototype for completing IND-enabling studies with the aim to conduct clinical studies in 2022. Details of the research program will be published in a scientific journal.

Story continues

The Company believes that its MicroDose-MN patch for delivering LSD and other psychedelics may enable flexible drug load capacity and combinations, controlled released delivery, and be able to present desired pharmacokinetic and safety profiles. In addition, the MicroDose-MN patch for psychedelics aims to empower patients to dose their medication remotely, safely and conveniently rather than under supervision by a healthcare provider at a certified medical office or hospital. To achieve this, the Company will incorporate anti-tampering and anti-abuse features that would parallel the approach used for the tamper-resistant transdermal fentanyl patch.

The Company is completing its evaluation of MicroDose-MN with 3,4-methylenedioxy-methamphetamine (MDMA) and N, N-dimethyltryptamine (DMT) and expects to provide results before the end of this year and pursue clinical studies in 2022.

The Company is actively engaged in partnering discussions for the use of its microneedle patch system to deliver psychedelics including, but not limited to, MDMA, LSD, DMT, ibogaine and mescaline. As such, PharmaTher offers potential partners a differentiated and validated delivery system for psychedelics, desired pharmacokinetic profiles, intellectual property protection, cGMP microneedle patches for IND-enabling and clinical studies, and a clear clinical pathway towards clinical studies in 2022.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics, such as ketamine, to treat mental health, neurological and pain disorders. PharmaTher is currently advancing an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics and infectious disease treatments.Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn.

For more business development opportunities or information about PharmaTher, please contact:

Fabio ChianelliChief Executive OfficerPharmaTher Holdings Ltd.Tel: 1-888-846-3171Email: info@pharmather.com Website: http://www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "potential", "aim", may and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the "Company") current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the period of August 31, 2021 ("MD&A"), dated October 27, 2021, which is available on the Company's profile at http://www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

The rest is here:

PharmaTher Announces Positive Research Results for LSD Microneedle Patch - Yahoo Finance

Posted in Psychedelics | Comments Off on PharmaTher Announces Positive Research Results for LSD Microneedle Patch – Yahoo Finance

MDMA could soon be used to treat PTSD according to physicians – Mixmag

Posted: at 10:32 am

According to a group of physicians in Scotland, MDMA could be used to treat post-traumatic stress disorder (PTSD) "within three years."

Doctor and psychotherapist James Hawkins wants medics to join up for training to examine how MDMA may assist manage mental illnesses.

Read this next: We went undercover in a Chinese MDMA factory

Hawkins, who treats patients with other psychedelics such as psilocybin, believes that studies demonstrate MDMA is extremely cost-effective.

In 2018, 76% of the 28 involved in a Phase Two trial undertaken in Colorado didn't meet the clinical diagnostic criteria of PTSD 12 months after receiving treatment.

The Multidisciplinary Association for Psychedelic Studies in California commissioned MDMA-assisted therapy research, which found that 67% of patients in the MDMA group no longer qualified for a PTSD diagnosis two months following treatment, compared to 32% in the placebo group.

Hawkins, who practises in Edinburgh and helped form the UK's Psychedelics Health Professionals Network, is afraid that therapy will be available before enough trained doctors are ready to provide it.

It is likely MDMA will be licensed for therapy in three years. There will be a big need for this in Scotland. But, who will be administering it?

Read this next: Scientists are recommending MDMA for treating mental health after lockdown

"I see us being able to do this and let professionals have an experience of psychedelics, he said.

"Psychedelic drugs still arent really part of the medical curriculum, other than in the context of these are harmful class A substances.

"Psychedelic-assisted therapy could save society billions in terms of reduced contact with mental health services, reduced presentations at A&E, less prescribing, regaining of lost productivity and improved physical health as a result of improved mental health".

Read this next: Molly: Everything but the girl

He hopes that his organisation, which is working to get charity status, will be able to assist.

Dr Jake Hawthorn, a psychiatrist in southeast Scotland who is interested in utilising psychedelics to treat addiction, believes that conventional medicine is recognising the need for new methods of treatment.

He said: "MDMA is expected to be licensed in the US in 2023. I think well follow within a couple of years, starting with psilocybin, maybe 2025.

"If doctors are keen to work with psychedelics, it could be highly beneficial for them to have experience of what the psychedelic entails."

[Via: The Times]

Aneesa Ahmed is Mixmag's Digital Intern, follow her on Twitter

View original post here:

MDMA could soon be used to treat PTSD according to physicians - Mixmag

Posted in Psychedelics | Comments Off on MDMA could soon be used to treat PTSD according to physicians – Mixmag